HIV pseudovirion vaccine exposing Env "fusion intermediates"-Response to immunisation in human CD4/CCR5-transgenic rats

Vaccine

Volumn 27, Issue 16, 2009, Pages 2202-2212

  Bosch, Valerie ^a   Pfeiffer, Tanya ^a   Devitt, Gerard ^a   Allespach, Ina ^b   Ebensen, Thomas ^c   Emerson, Vanessa ^a   Guzman, Carlos A ^c   Keppler, Oliver T ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

HIV 1 vaccine; Induced Env epitope; Neutralising antibodies

Indexed keywords

ANTISERUM; CD4 ANTIGEN; CELL PROTEIN; CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOMER; NEUTRALIZING ANTIBODY; VIRUS RECEPTOR;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONFORMATION; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC RAT; VIRION; VIRUS TITRATION;

AIDS VACCINES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RATS; RATS, TRANSGENIC; RECEPTORS, CCR5; VIRION;

EID: 62149100724     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.014     Document Type: Article

References (54)

1. Zwick M.B., and Burton D.R. HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr HIV Res 5 6 (2007) 608-624
2. Pantophlet R., and Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24 (2006) 739-769
3. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 455 7213 (2008) 613-619
4. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 5187 (1994) 1024-1027
5. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10 4 (1994) 359-369
6. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70 2 (1996) 1100-1108
7. Conley A.J., Kessler II J.A., Boots L.J., Tung J.S., Arnold B.A., Keller P.M., et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci U S A 91 8 (1994) 3348-3352
8. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67 11 (1993) 6642-6647
9. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75 22 (2001) 10892-10905
10. DeVico A.L. CD4-induced epitopes in the HIV envelope glycoprotein, gp120. Curr HIV Res 5 6 (2007) 561-571
11. Devico A., Silver A., Thronton A.M., Sarngadharan M.G., and Pal R. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. Virology 218 1 (1996) 258-263
12. Fouts T., Godfrey K., Bobb K., Montefiori D., Hanson C.V., Kalyanaraman V.S., et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci U S A 99 18 (2002) 11842-11847
13. Kang C.Y., Hariharan K., Nara P.L., Sodroski J., and Moore J.P. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120. J Virol 68 9 (1994) 5854-5862
14. Xiao X., Phogat S., Shu Y., Phogat A., Chow Y.H., Wei O.L., et al. Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity. Vaccine 21 27-30 (2003) 4275-4284
15. Varadarajan R., Sharma D., Chakraborty K., Patel M., Citron M., Sinha P., et al. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. J Virol 79 3 (2005) 1713-1723
16. Sparacio S., Pfeiffer T., Holtkotte D., and Bosch V. Inter-retroviral fusion mediated by human immunodeficiency virus or murine leukemia virus glycoproteins: independence of cellular membranes and membrane vesicles. Virology 294 2 (2002) 305-311
17. Sparacio S., Zeilfelder U., Pfeiffer T., Henzler T., and Bosch V. Membrane fusion between retroviral particles: host-range extension and vaccine prospects. Virology 271 2 (2000) 248-252
18. Zhou J., and Aiken C. Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope. J Virol 75 13 (2001) 5851-5859
19. Binley J.M., Sanders R.W., Clas B., Schuelke N., Master A., Guo Y., et al. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74 2 (2000) 627-643
20. Binley J.M., Cayanan C.S., Wiley C., Schulke N., Olson W.C., and Burton D.R. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 77 10 (2003) 5678-5684
21. Abrahamyan L.G., Markosyan R.M., Moore J.P., Cohen F.S., and Melikyan G.B. Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. J Virol 77 10 (2003) 5829-5836
22. Devitt G., Emerson V., Pisch T., Keppler O.T., and Bosch V. Analysis of the exposure of induced HIV glycoprotein epitopes in a potential HIV pseudovirion vaccine. Vaccine 25 12 (2007) 2161-2167
23. Munch J., Rucker E., Standker L., Adermann K., Goffinet C., Schindler M., et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 131 6 (2007) 1059-1071
24. Keppler O.T., Welte F.J., Ngo T.A., Chin P.S., Patton K.S., Tsou C.L., et al. Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med 195 6 (2002) 719-736
25. Goffinet C., Allespach I., and Keppler O.T. HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc Natl Acad Sci U S A 104 3 (2007) 1015-1020
26. Goffinet C., Michel N., Allespach I., Tervo H.M., Hermann V., Krausslich H.G., et al. Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression. Retrovirology 4 (2007) 53
27. Devitt G., Thomas M., Klibanov A.M., Pfeiffer T., and Bosch V. Optimized protocol for the large scale production of HIV pseudovirions by transient transfection of HEK293T cells with linear fully deacylated polyethylenimine. J Virol Methods 146 1-2 (2007) 298-304
28. Devitt G., Emerson V., Holtkotte D., Pfeiffer T., Pisch T., and Bosch V. Incorporation of chimeric HIV-SIV-Env and modified HIV-Env proteins into HIV pseudovirions. Virology 361 2 (2007) 465-471
29. Chesebro B., Wehrly K., Nishio J., and Perryman S. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism. J Virol 66 11 (1992) 6547-6554
30. Abacioglu Y.H., Fouts T.R., Laman J.D., Claassen E., Pincus S.H., Moore J.P., et al. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies. AIDS Res Hum Retroviruses 10 4 (1994) 371-381
31. Chesebro B., and Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol 62 10 (1988) 3779-3788
32. Bosch V., and Pawlita M. Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site. J Virol 64 5 (1990) 2337-2344
33. Lampe M., Briggs J.A., Endress T., Glass B., Riegelsberger S., Krausslich H.G., et al. Double-labelled HIV-1 particles for study of virus-cell interaction. Virology 360 1 (2007) 92-104
34. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 6584 (1996) 661-666
35. He J., Choe S., Walker R., Di Marzio P., Morgan D.O., and Landau N.R. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69 11 (1995) 6705-6711
36. Ebensen T., Schulze K., Riese P., Link C., Morr M., and Guzman C.A. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties. Vaccine 25 8 (2007) 1464-1469
37. Cazorla S.I., Becker P.D., Frank F.M., Ebensen T., Sartori M.J., Corral R.S., et al. Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun 76 1 (2008) 324-333
38. Henriksson P., Pfeiffer T., Zentgraf H., Alke A., and Bosch V. Incorporation of wild-type and C-terminally truncated human epidermal growth factor receptor into human immunodeficiency virus-like particles: insight into the processes governing glycoprotein incorporation into retroviral particles. J Virol 73 11 (1999) 9294-9302
39. Derdeyn C.A., Decker J.M., Sfakianos J.N., Wu X., O'Brien W.A., Ratner L., et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74 18 (2000) 8358-8367
40. Platt E.J., Wehrly K., Kuhmann S.E., Chesebro B., and Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72 4 (1998) 2855-2864
41. Vzorov A.N., Bukrinsky M.I., Grigoriev V.B., Tentsov Y., and Bukrinskaya A.G. Highly immunogenic human immunodeficiency viruslike particles are produced by recombinant vaccinia virus-infected cells. AIDS Res Hum Retroviruses 7 1 (1991) 29-36
42. Rovinski B., Haynes J.R., Cao S.X., James O., Sia C., Zolla-Pazner S., et al. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine. J Virol 66 7 (1992) 4003-4012
43. Montefiori D.C., Safrit J.T., Lydy S.L., Barry A.P., Bilska M., Vo H.T., et al. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J Virol 75 13 (2001) 5879-5890
44. Lifson J.D., Rossio J.L., Piatak Jr. M., Bess Jr. J., Chertova E., Schneider D.K., et al. Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins. AIDS Res Hum Retroviruses 20 7 (2004) 772-787
45. Lifson J.D., Piatak Jr. M., Rossio J.L., Bess Jr. J., Chertova E., Schneider D., et al. Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challenge. J Med Primatol 31 4-5 (2002) 205-216
46. Haynes J.R., Cao S.X., Rovinski B., Sia C., James O., Dekaban G.A., et al. Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines. AIDS Res Hum Retroviruses 7 1 (1991) 17-27
47. Hammonds J., Chen X., Fouts T., DeVico A., Montefiori D., and Spearman P. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J Virol 79 23 (2005) 14804-14814
48. Haffar O.K., Smithgall M.D., Moran P.A., Travis B.M., Zarling J.M., and Hu S.L. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like gag-env particles. Virology 183 2 (1991) 487-495
49. Buonaguro L., Visciano M.L., Tornesello M.L., Tagliamonte M., Biryahwaho B., and Buonaguro F.M. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol 79 11 (2005) 7059-7067
50. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13 9 (2007) 1032-1034
51. Yao Q., Bu Z., Vzorov A., Yang C., and Compans R.W. Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine 21 7-8 (2003) 638-643
52. Crooks E.T., Moore P.L., Franti M., Cayanan C.S., Zhu P., Jiang P., et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366 2 (2007) 245-262
53. Moore P.L., Crooks E.T., Porter L., Zhu P., Cayanan C.S., Grise H., et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80 5 (2006) 2515-2528
54. Willey S., and Aasa-Chapman M.M. Humoral immunity to HIV-1: neutralisation and antibody effector functions. Trends Microbiol (2008)